SureTrader
Nadex Advertisement
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs > Peregrine Pharmaceuticals (PPHM)

I don't know about the rest of you,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
pphmtoolong Member Profile
 
Followed By 26
Posts 3,644
Boards Moderated 0
Alias Born 07/17/06
160x600 placeholder
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/25/2017 5:00:15 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 7/21/2017 4:12:16 PM
Statement of Ownership (sc 13g) "Edgar (US Regulatory)" - 7/20/2017 4:21:29 PM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) "Edgar (US Regulatory)" - 7/20/2017 12:43:22 PM
Ronin Trading and SW Investment Management Issue Letter to Employees of Peregrine Pharmaceuticals "PR Newswire (US)" - 7/20/2017 8:30:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/14/2017 4:49:23 PM
Amended Statement of Beneficial Ownership (sc 13d/a) "Edgar (US Regulatory)" - 7/14/2017 4:31:03 PM
Amended Statement of Beneficial Ownership (sc 13d/a) "Edgar (US Regulatory)" - 7/14/2017 4:28:39 PM
Peregrine Pharmaceuticals Reports Financial Results for Quarter and Fiscal Year Ended April 30, 2017 and Recent Developments "GlobeNewswire Inc." - 7/14/2017 4:14:02 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) "Edgar (US Regulatory)" - 7/14/2017 7:53:56 AM
Peregrine Pharmaceuticals Issues Statement Regarding Ronin Trading and SW Investment Management’s Letter to Stockholders "GlobeNewswire Inc." - 7/13/2017 6:08:59 PM
Additional Proxy Soliciting Materials - Non-management (definitive) (dfan14a) "Edgar (US Regulatory)" - 7/13/2017 5:01:34 PM
Ronin Trading and SW Investment Management Issue Letter to Stockholders of Peregrine Pharmaceuticals "PR Newswire (US)" - 7/13/2017 8:55:00 AM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 7/7/2017 5:05:55 PM
Peregrine to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2017 After Market Close on July 14, 2017 "GlobeNewswire Inc." - 7/7/2017 4:05:00 PM
Peregrine Pharmaceuticals Announces Reverse Stock Split "GlobeNewswire Inc." - 7/7/2017 10:25:00 AM
Announcing VanEck Vectors Equity ETF’s June 2017 Distributions "Business Wire" - 6/30/2017 5:27:00 PM
Amended Statement of Beneficial Ownership (sc 13d/a) "Edgar (US Regulatory)" - 6/29/2017 5:26:08 PM
Amended Statement of Beneficial Ownership (sc 13d/a) "Edgar (US Regulatory)" - 6/20/2017 5:27:00 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/7/2017 4:33:15 PM
Current Report Filing (8-k) "Edgar (US Regulatory)" - 6/6/2017 4:26:06 PM
Peregrine Pharmaceuticals Declares Quarterly Dividend on its Series E Convertible Preferred Stock "GlobeNewswire Inc." - 6/6/2017 4:05:00 PM
Peregrine Pharmaceuticals Presents Preliminary Correlative Analysis of PD-L1 Expression from SUNRISE Trial at ASCO 2017 "GlobeNewswire Inc." - 6/5/2017 8:05:00 AM
Amended Statement of Beneficial Ownership (sc 13d/a) "Edgar (US Regulatory)" - 5/19/2017 4:36:33 PM
Statement of Changes in Beneficial Ownership (4) "Edgar (US Regulatory)" - 4/28/2017 7:00:04 PM
pphmtoolong   Tuesday, 04/24/12 10:44:52 AM
Re: None
Post # of 305739 
I don't know about the rest of you, but I bought this stock based on Thorpe's approved patents and the early Bavi clinical studies.

It seems that Peregrine management and BOD have done everything reasonable to forward the Bavi agenda given the limited financial resources available. Running the trials overseas in Georgia and India could not have been easy, but they did it and got promising results. As in many other cases Bavi may not pan out in later stage trials. I don't blame management for trying with Bavi, and I don't blame management for the perversity of Mother Nature. I could blame them for excessive optimism, but the science seemed sound to them just as it seemed sound to us.

I don't like that managment has diluted the heck out of our stock, but I really don't buy any of the alternative financing plans I've seen presented here. I am a retired CPA; so I have some confidence assessment on this point.

If Bavi finally hits it out of the park with second line NSCLC, there is still a chance for us to make money. Otherwise, this has been a very expensive lesson in wishful thinking on biotechs. I blame only myself if Peregrine flops. I never should have thrown so much money into such a crap shoot.

Paul


Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist